Cambridge Innovation Capital is an established VC firm embedded in the UK technology ecosystem with privileged access to the University of Cambridge. The firm manages over £600m of capital and invests across deep tech and life sciences.
The funding round was led by SoftBank Vision Fund 2 and co-led by Ally Bridge Group to support international expansion and technological development.
"This latest financing equips CMR with significant funds to accelerate our mission of bringing Versius to hospitals worldwide, whilst providing full flexibility to achieve our goals. This major injection of capital that now values us at $3billion not only reflects the level of interest we have seen in our product, but also the scale of the business, and will enable significant technology developments and global expansion. As the lead investor, SoftBank has a wealth of experience supporting disruptive business models and innovative technologies, and we look forward to leveraging their expertise and extensive ecosystem. I would also like to thank our existing investors for their long-term support."
Barclays led the funding round with participation from existing backers to accelerate international expansion and product development.
"This investment recognises that with powerful real-time software solutions underpinning our emerging green energy systems, tackling the world’s greatest threat of climate change can also become the world’s greatest commercial opportunity. Barclays shares our vision and has a broad customer base in the UK and internationally, which includes many energy businesses. I am looking forward to working with them to help achieve our ambitious goals."
Koch Disruptive Technologies led the Series B round to support the commercialisation of the Veros diagnostics platform.
"This Series B round is crucial in providing us with the resources to grow our Veros platform to revolutionize decentralized point-of-care testing; and it is particularly important as we commercialize our Veros COVID-19 test, which delivers laboratory quality results directly to users within minutes, without an instrument. This will be an essential tool in the effective management of outbreaks of this and other diseases,"
The financing round drew participation from Legal & General, Tencent, and QVentures to support genomics software development.
"We are thrilled to be supporting Congenica in developing their world-leading technology to deliver life-changing answers. At QVentures, we strive to support cutting-edge technology companies that really change how an industry operates and we believe David and his team are doing just that. We are pleased that QVentures’ Family Offices and UHNWI investors could join us on that journey."
The financing will support international expansion and development of the Deltaflow operating system.
"For a quantum ecosystem to thrive, we urgently need an operating system. An operating system makes quantum computers useful – it allows programs and applications to run on many different machines. Riverlane aims to make our operating system Deltaflow a global standard."
.png)
